These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 31200820)

  • 1. Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio.
    Shinde A; Horne ZD; Li R; Glaser S; Massarelli E; Koczywas M; Erhunmwunsee L; Reckamp KL; Weksler B; Salgia R; Beriwal S; Amini A
    Lung Cancer; 2019 Jul; 133():136-143. PubMed ID: 31200820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratio.
    Renaud S; Falcoz PE; Olland A; Reeb J; Santelmo N; Massard G
    Interact Cardiovasc Thorac Surg; 2015 Feb; 20(2):222-7. PubMed ID: 25413781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of postmastectomy and regional nodal radiation after neoadjuvant chemotherapy for clinically lymph node-positive breast cancer: a National Cancer Database (NCDB) analysis.
    Rusthoven CG; Rabinovitch RA; Jones BL; Koshy M; Amini A; Yeh N; Jackson MW; Fisher CM
    Ann Oncol; 2016 May; 27(5):818-27. PubMed ID: 26861597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathologic nodal clearance and complete response following neoadjuvant chemoradiation for clinical N2 non-small cell lung cancer: Predictors and long-term outcomes.
    Haque W; Verma V; Butler EB; Teh BS
    Lung Cancer; 2019 Apr; 130():93-100. PubMed ID: 30885358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of consolidation therapy for stage III non-small cell lung cancer with persistent N2 disease after induction chemotherapy.
    Amini A; Correa AM; Komaki R; Chang JY; Tsao AS; Roth JA; Swisher SG; Rice DC; Vaporciyan AA; Lin SH
    Ann Thorac Surg; 2012 Sep; 94(3):914-20. PubMed ID: 22819472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical study on the effects of neoadjuvant chemotherapy on lymph node ratio, prognosis, and survival analysis of stage ⅢA-N2 non-small cell lung cancer].
    Wei YL; Cui YH; Dong YH; Shi WJ
    Zhonghua Yi Xue Za Zhi; 2021 Jan; 101(4):259-264. PubMed ID: 33486934
    [No Abstract]   [Full Text] [Related]  

  • 7. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival.
    Bueno R; Richards WG; Swanson SJ; Jaklitsch MT; Lukanich JM; Mentzer SJ; Sugarbaker DJ
    Ann Thorac Surg; 2000 Dec; 70(6):1826-31. PubMed ID: 11156079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating the fate of patients who undergo resections of very large, node-negative lung cancers using the National Cancer DataBase.
    Liu J; Hancock JG; Moreno AC; Wang Z; Boffa DJ; Detterbeck FC; Kim AW
    Eur J Cardiothorac Surg; 2016 Feb; 49(2):596-601. PubMed ID: 25890936
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer.
    Urban D; Bar J; Solomon B; Ball D
    J Thorac Oncol; 2013 Jul; 8(7):940-6. PubMed ID: 23695418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lymph node ratio as a prognostic factor in patients with pathological N2 non-small cell lung cancer.
    Tamura M; Matsumoto I; Saito D; Yoshida S; Takata M; Takemura H
    World J Surg Oncol; 2016 Nov; 14(1):295. PubMed ID: 27884195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prognostic score system with lymph node ratio in stage IIIA-N2 NSCLC patients after surgery and adjuvant chemotherapy.
    Han H; Zhao Y; Gao Z; Zheng D; Fu F; Zhao Z; Tang Y; Xiang J; Sun Y; Hu H; Chen H
    J Cancer Res Clin Oncol; 2019 Aug; 145(8):2115-2122. PubMed ID: 31175463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Log odds of positive lymph nodes may predict survival benefit in patients with node-positive non-small cell lung cancer.
    Deng W; Xu T; Wang Y; Xu Y; Yang P; Gomez D; Liao Z
    Lung Cancer; 2018 Aug; 122():60-66. PubMed ID: 30032846
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome of Patients With pN2 "Potentially Resectable" Nonsmall Cell Lung Cancer Who Underwent Surgery After Induction Chemotherapy.
    Spaggiari L; Casiraghi M; Guarize J; Brambilla D; Petrella F; Maisonneuve P; De Marinis F
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):593-602. PubMed ID: 28043483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of residual nodal burden using lymph node ratio in locally advanced breast cancer after neoadjuvant chemotherapy.
    Agarwal R; Philip A; Pavithran K; Rajanbabu A; Goel G; Vijaykumar DK
    Indian J Cancer; 2019; 56(3):228-235. PubMed ID: 31389386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Surgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survival.
    Decaluwé H; De Leyn P; Vansteenkiste J; Dooms C; Van Raemdonck D; Nafteux P; Coosemans W; Lerut T
    Eur J Cardiothorac Surg; 2009 Sep; 36(3):433-9. PubMed ID: 19502079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is There a Survival Benefit in Patients With Stage IIIA (N2) Non-small Cell Lung Cancer Receiving Neoadjuvant Chemotherapy and/or Radiotherapy Prior to Surgical Resection: A Systematic Review and Meta-analysis.
    Xu YP; Li B; Xu XL; Mao WM
    Medicine (Baltimore); 2015 Jun; 94(23):e879. PubMed ID: 26061306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment clinical mediastinal nodal bulk and extent do not influence survival in N2-positive stage IIIA non-small cell lung cancer patients treated with trimodality therapy.
    Lee H; Ahn YC; Pyo H; Kim B; Oh D; Nam H; Lee E; Sun JM; Ahn JS; Ahn MJ; Park K; Choi YS; Kim J; Zo JI; Shim YM
    Ann Surg Oncol; 2014 Jun; 21(6):2083-90. PubMed ID: 24522994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of metastatic lymph node ratio in predicting the prognosis of non-small cell lung cancer patients].
    Li Y; Sun BS; Zhang ZF; Zhang LM; Wang CL
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(24):1682-6. PubMed ID: 21914316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship Between Radiation Therapy Dose and Outcome in Patients Treated With Neoadjuvant Chemoradiation Therapy and Surgery for Stage IIIA Non-Small Cell Lung Cancer: A Population-Based, Comparative Effectiveness Analysis.
    Sher DJ; Fidler MJ; Seder CW; Liptay MJ; Koshy M
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):307-16. PubMed ID: 25838187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer.
    Taylor MD; LaPar DJ; Thomas CJ; Persinger M; Stelow EB; Kozower BD; Lau CL; Jones DR
    Ann Thorac Surg; 2013 Oct; 96(4):1163-1170. PubMed ID: 23998409
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.